Page 8 - Biomedical Technology News Today

In addition to AD, brepocitinib, a topical TYK2/JAK1 inhibitor, is being developed as a treatment for dermatomyositis, SLE, hidradenitis suppurativa, and non-infectious uveitis.

CAMBRIDGE, Mass., Nov. 29, 2022, which recognizes novel technologies that have improved human health. Each year, the prize will celebrate a novel technology and recognize up to four key individuals

Nominations Open for the Merkin Prize in Biomedical Technology GlobeNewswire November 29, 2022 CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology, which recognizes novel technologies that have improved human health. Each year, the prize will...

Merkin Prize Logo The Richard N. Merkin Prize in Biomedical Technology is accepting nominations until Jan. 30, 2023. CAMBRIDGE, Mass. - November 29, 2022 - (Newswire.com) Nominations ar...

Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.

India AMR Innovation Hub is a unique Convergent Think Tank on AMR Interventions, with Indian and global stakeholders

Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company's total funding to date to nearly $82 million. The funds will help support Cresilon's entrance into the human health market, as its gel is currently used only by veterinarians.

Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology

CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology,...

A microbiologist reflects on the use of horseshoe crabs by the pharmaceutical industry for the potent endotoxin detector in their blood and why it might be time to stop.